Breakthroughs in the treatment of colorectal cancer in the fourth phase, successful cases: HER2-positive patients used the targeted treatment combination of tucatinib and trastuzumab to achieve no signs of disease after one year. The complete course from the failure of chemotherapy to the success of targeted therapy demonstrates the importance of genetic testing to guide personalized treatment. Learn about the efficacy of tucatinib in HER2-positive colorectal cancer and how targeted therapy can bring new hope and improved quality of life to patients with advanced cancer.
